Your SlideShare is downloading. ×
Ur12 4 5
Ur12 4 5
Ur12 4 5
Ur12 4 5
Ur12 4 5
Ur12 4 5
Ur12 4 5
Ur12 4 5
Ur12 4 5
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Ur12 4 5


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Progress admit day 9 (31/3/53)
    • ระหว่างนอน รพ . ผู้ป่วยมีไข้ 38c, no organ specific symptoms
    • H/C: Gram positive cocci in chain x II
    • Repeat H/C: Grampositive cocci in chain x III
    • Identify = S.bovis I MIC sense to Penicillin
  • 2. W/U Infective endocarditis
    • Echo 31/3/53: dense echo mass at both mitral leaflet , mild MR, mild MS, LVEF 74%
    • Eye ground: Roth’s spot positive
    • Imp: subacute bacterial endocarditis
    • ให้การรักษาด้วย PGS 24 million units/day + Gentamicin 1 mg/kg q8hr
  • 3.  
  • 4. Onset of IE
    • 1+ ปีก่อน TTE 17/3/52: Normal LVEF, no RWMA, no clot nor vegetation, slightly thickened AV
    • TEE 18/3/52: Normal TEE study
    • 6 เดือนก่อน ( 22/10/52)
      • S.epidermidis xI
      • Anaerobic gram positive rods xII
      • ให้การรักษาด้วย Ceftriaxone IV 2 days then Omnicef 11 days
  • 5. Onset of IE
    • 4 เดือนก่อน (21/12/52-4/1/52)
      • H/C NG x II
    • 2 สัปดาห์ก่อน (9/3/53)
      • Microaerophilic streptococcus x II
      • ให้การรักษาด้วย Ceftazodime IV 4 days then Ciprofloxacin 10 days
  • 6. Stroke in Infective endocarditis
    • All neurologic complications occurred more often with S . a ureus infection (67%) than with viridans streptococci (22%)
    • In native-valve endocarditis, most (74%) ischemic strokes had occurred by the time of presentation .
    • Patients with infective endocarditis and ischemic stroke on presentation seldom had recurrent emboli after the infection was controlled .
    • A nticoagulants and surgery are not warranted to prevent recurrent stroke in these patients .
    Merrill C. Kanter and Robert G. Hart . Neurologic complications of infective endocarditis . Neurology 1991;41;1015 RG Hart, JW Foster, MF Luther and MC Kanter . S troke in infective endocarditis Stroke . 1990;21;695-700
  • 7. Anticoagulant in S. aureus IE
    • Left - sided S aureus IE (native valve 35 pt, prosthetic valve 21 pt)
    • Of the prosthetic valve IE, 19 (90%) were taking oral anticoagulant therapy at the time of diagnosis while no patient with native valve IE was receiving such treatment.
    • Mortality was higher in prosthetic valve IE than in native valve IE (71% vs 37%; P =.02). No patient with native valve IE died due to central nervous system complications, while 73% (11 of 15 patients) with prosthetic valve IE died due to central nervous system complications.
    Pilar Tornos, et al. Infective Endocarditis Due to Staphylococcus aureus . Arch Intern Med . 1999;159:473-475.
  • 8. Anticoagulatio n in IE
    • In pt with native valve disease, the benefit of anticoagulation has never been demonstrated convincingly.
    • C ontroversial, particularly in mechanical valve endocarditis.
    • In contrast, some authorities recommend continuation of therapy in patients with mechanical prosthetic valve IE; however, the general advice is to discontinue all anticoagulation in patients with S aureus prosthetic valve IE who have experienced a recent central nervous system embolic event for at least the first 2 weeks of antibiotic therapy .
    • Until further definitive data are available, the routine use of aspirin for established endocarditis is not r ecommended (Class III, Level of Evidence: B).
    Larry M. Baddour et al. Infective Endocarditis . Circulation . 2005; 111:e394-e433 .
  • 9. Anticoagulatio n in IE
    • There is no indication for the initiation of antithrombotic drugs (thrombolytic drugs, anticoagulant or antiplatelet therapy) during the active phase of IE. In patients already taking oral anticoagulants, there is a risk of intracranial haemorrhage which seems to be highest in patients with S. aureus PVE and those with a previous neurological event. The recommendations for the management of the anticoagulant therapy are based on low level of evidence .
    European Society of Cardiology . Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009) . European Heart Journal (2009) 30, 2369–2413